ࡱ> :<9 @ bjbjʚʚ .,$ ^6666ZkVXXXXXX$R$|  |66""" 66V" V"""6 p" "V0"; ;";"4" % || :Best Treatment of Prostate Cancer in Older Men: Brachytherapy, IMRT IGRT. Research suggests aggressive treatment is viable, even for patients in their late 70s By Karen Pallarito & Benjamin Guix MD PhD MBA HealthDay Reporter FRIDAY, Oct. 17 (HealthDay News) -- With increasing life expectancies, improved surgical tools, and better information on patient results, many older men diagnosed with early prostate cancer are taking a pass on the traditional advice to hold off on treatment for a period of time. So-called "watchful waiting" -- or closely monitoring the cancer's progression -- is still a viable option. But many experts now believe that aggressive treatment -- even for older men -- may be the better way to go. "We're pushing the limits on the upper end," said Dr. Edouard J. Trabulsi, assistant professor in the department of urology at Jefferson Medical College and co-director of the Jefferson Prostate Diagnostic Center in Philadelphia. Patients who undergo curative treatment are doing much better that patients who choose to have less agresive therapy or expectancy Professor Dr Benjamin Guix, professor of Radiotherapy and Head of the Radiation Oncology Departement of the IMOR Foundation at Barcelona. A study published recently in the Journal of the American Medical Association helped shake up the conventional wisdom. The study, which involved some 44,000 men, found that the death risk for those who received prostate cancer treatment was nearly one-third lower than for men who received no treatment. And that was true across all age categories, including the oldest men in the study, aged 75 to 80. "We often think of prostate cancer as an indolent disease, and it is for many men, which is why observation is a very reasonable treatment option for patients with low and intermediate risk disease," said the study's lead author, Dr. Yu-Ning Wong, a medical oncologist at the Fox Chase Cancer Center in Philadelphia. "However, the life expectancy for a 70-year-old man is about 13 years, and patients who are otherwise healthy should recognize that if they live long enough, they may be at risk of developing complications from prostate cancer," professor Guix added. Prostate cancer is the second most common type of cancer in American men, after skin cancer. In 2008, about 186,320 new cases of the disease will be diagnosed, and about 28,660 men will die from it, according to the American Cancer Society. Because prostate cancer is generally a slow-growing cancer, some men may never need treatment. And for many older men without symptoms, watchful waiting has been recommended, because it was believed they would die from other causes before their cancer advanced. But as men's life expectancy creeps higher and new robotic techniques improve the precision of radiotherapy and the quality of Brachytherapy, the decision is becoming more complicated. "Patients should understand the risks and benefits of all their treatment options -- radiation, brachytherapy, surgery and observation," Wong noted. "If they choose observation, they should be committed to careful follow-up with their physicians for the rest of their lives." Watchful waiting does not mean watching someone die. Many oncologists today prefer the term "active surveillance," Guix said, because it more accurately describes the diligent approach to monitoring these patients, including the use of PSA blood tests, digital rectal exams and biopsies of the prostate to detect changes in the cancer. Still, determining the best course of treatment is difficult, because there isn't good data to help guide patients and their families on the effectiveness and harms of treatments for clinically localized prostate cancer, according to a recent literature review prepared for the federal Agency for Healthcare Research and Quality. A recent work published in the International Journal of Radiation Oncology, Biology and Physics, demonstarted that the patients who were treated by brachytherapya as apart of their treatment were enjoying beter quality of life than patients treated with surgery or hormonal treatment. But oncologists hope to have better information on the benefits and risks of active surveillance, also known as "expectant management," compared with treatment, by late next year. The National Cancer Institute and the Department of Veterans Affairs are co-sponsoring a study, called the Prostate Cancer Intervention Versus Observation Trial, to compare radical prostatectomy -- which is removal of the gland -- and expectant management on patient survival and overall quality of life. For now, Wong advises: "They [patients] should place the potential benefit of treatment found in our study in the context of the potential side effects of treating the patient's other medical problems." More information For more on treatments for prostate cancer, visit the IMOR Foundation web site  HYPERLINK "http://www.imor.org" www.imor.org, the  HYPERLINK "http://www.telefonica.net/web2/benjaminguix" www.telefonica.net/web2/benjaminguix  HYPERLINK "http://www.telefonica.net/web2/bguix" www.telefonica.net/web2/bguix  HYPERLINK "http://www.telefonica.net/web2/b_guix" www.telefonica.net/web2/b_guix or the  HYPERLINK "http://www.cancer.gov/cancertopics/prostate-cancer-treatment-choices/" \t "_new" National Cancer Institute. SOURCES: Yu-Ning Wong, M.D., medical oncologist, Fox Chase Cancer Center, Philadelphia; Edouard J. Trabulsi, M.D., assistant professor, department of urology, Jefferson Medical College, and co-director, Jefferson Prostate Diagnostic Center, and co-director, Genito-Urinary Multidisciplinary Cancer Clinic, Kimmel Cancer Center, Philadelphia; Dec. 13, 2006, Journal of the American Medical Association; American Cancer Society; Feb. 4, 2008, Annals of Internal Medicine, online .IJ  gB^éáÓ|h|N|h|h|h|h|h|h|3h{Lh{L6B*CJOJQJ]aJmH ph333sH 'hZ^B*CJOJQJaJmH ph333sH -h{Lh{LB*CJOJQJaJmH ph333sH h{Lh{L6]mH sH he_mH sH 3h{Lh{L5B* CJOJQJ\aJmH ph!5`sH h{Lh{LmH sH 3h{Lh{L5B* CJ!OJQJ\aJ!mH ph!5`sH -hSv5B* CJ!OJQJ\aJ!mH ph!5`sH  `Lagd{Lgd{L+,MNO[\bcκuVu:6jh"5B*CJOJQJU\aJmH ph333sH <jhh[!sB*CJOJQJUaJmH ph333sH hh[!s0JmH sH <jhh[!sB*CJOJQJUaJmH ph333sH 0jh[!sB*CJOJQJUaJmH ph333sH 'h[!sB*CJOJQJaJmH ph333sH -h{Lh{LB*CJOJQJaJmH ph333sH 3h{Lh{L5B*CJOJQJ\aJmH ph333sH LMNlmnrvwƪ{gP;P;(jh{LB*CJOJQJUaJph333-h{Lh{LB*CJOJQJaJmH ph333sH 'h[!sB*CJOJQJaJmH ph333sH Bjhf&h"5B*CJOJQJU\aJmH ph333sH hf&h"0JmH sH 6jh"5B*CJOJQJU\aJmH ph333sH Bjhf&h"5B*CJOJQJU\aJmH ph333sH -h"5B*CJOJQJ\aJmH ph333sH XǭǭǢh{Lh{LmH sH 3h{Lh{L6B*CJOJQJ]aJmH ph333sH -h{Lh{LB*CJOJQJaJmH ph333sH (jh{LB*CJOJQJUaJph333h{Lh{L0JmH sH ,1h. A!"#$% DyK  www.imor.orgyK *http://www.imor.org/DyK %www.telefonica.net/web2/benjaminguixyK Xhttp://www.telefonica.net/web2/benjaminguixDyK www.telefonica.net/web2/bguixyK bhttp://www.telefonica.net/web2/bguixyX;H,]ą'cDyK www.telefonica.net/web2/b_guixyK dhttp://www.telefonica.net/web2/b_guixyX;H,]ą'c@@@ NormalCJ_HaJmH sH tH NA@N Fuente de prrafo predeter.RiR  Tabla normal4 l4a ,k, Sin listaRU@R {L Hipervnculo"5>*CJOJQJ\aJo(ph3VOV {Lbylinedd[$\$5B*CJOJQJ\aJph333B^@B {L Normal (Web)dd[$\$NV@!N "Hipervnculo visitado >*B* ph,` L a 000000p0000000 0000000pO90 O90M90O90+N[bMlvXXXXX8@0(  B S  ? _Hlt231837253 _Hlt231837254 _Hlt231837265X@@@Y9J\q:J0;J5<J5=J<6>J|6?J6@J6AJ<7BJWCJWDJXEJTXFJXGJXHJYIJTYJJ,TKJlTLJTUU_gOttx~     ^fnn\w}  8 *urn:schemas-microsoft-com:office:smarttagsCity=*urn:schemas-microsoft-com:office:smarttags PlaceType=*urn:schemas-microsoft-com:office:smarttags PlaceName9*urn:schemas-microsoft-com:office:smarttagsplace>*urn:schemas-microsoft-com:office:smarttags PersonName   0=?CDH "*X\MQ  M P ]iO[Nl  5;KRV^`c39 3DH+\bn{Le_[!sSvvZ^"@/O@@UnknownGz Times New Roman5Symbol3& z Arial7&  Verdana"qjf ֆP )P )!243H ?{LdBest treatment for Prostate Cancer Brachytherapy Doctor Benjamin Guix Melcior Radiotherapy IMRT IGRT BENJAMIN GUIX FAMILIA GUIXOh+'0,8DT lx   hBest treatment for Prostate Cancer Brachytherapy Doctor Benjamin Guix Melcior Radiotherapy IMRT IGRTBENJAMIN GUIXNormalFAMILIA GUIX5Microsoft Word 10.0@`4<@T4@!P՜.+,D՜.+,` hp  ACASA-IMOR-ICRO-CORMEN)  eBest treatment for Prostate Cancer Brachytherapy Doctor Benjamin Guix Melcior Radiotherapy IMRT IGRT Ttulo 8@ _PID_HLINKSA Fhttp://www.cancer.gov/cancertopics/prostate-cancer-treatment-choices/= &http://www.telefonica.net/web2/b_guix%http://www.telefonica.net/web2/bguixna,http://www.telefonica.net/web2/benjaminguixG^http://www.imor.org/